Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...

Janssen-Cilag International NV, part of Johnson & Johnson, has announced encouraging results from the phase 1b/2 OrigAMI-4 ...

AstraZeneca’s Saphnelo (anifrolumab) has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for approval in the European Union as a self-administered, ...

Adocia and Tonghua Dongbao have announced positive topline results from a phase 3 clinical trial of BioChaperone Lispro ...

The National Institute for Health and Care Research (NIHR) has announced a £157 million investment over 5 years to support 10 ...

Artificial intelligence tools that could revolutionise patient care are being trialled in phase 2 of the Medicines and ...

AbbVie has announced new clinical data from its antibody-drug conjugate (ADC) platform, reinforcing its commitment to ...

Eligible patients in Scotland with relapsed or refractory multiple myeloma will now have access to a new treatment option ...

Women in Scotland suffering from endometriosis now have access to a new treatment option following the Scottish Medicines ...

Kainos has announced a new contract of up to three years with NHS England to enhance digital preventative healthcare services ...

Men with BRCA1 and BRCA2 gene mutations should be offered annual PSA testing from the age of 40 to detect prostate cancer at ...